CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026 ASCO Annual Meeting, CellOrigin's scientific co-founder's team presented two new studies on solid tumor cell therapy. The first, CAR-Mix™ multicellular synergistic therapy, combines...
Amorepacific Holdings Signs Strategic Investment Agreement with HIGHER Corporation on Beauty and Medical Aesthetics Collaboration
Partnership to explore solutions connecting Amorepacific's skin science with HIGHER Corporation's medical aesthetics expertise SEOUL, South Korea, July 31, 2026 /PRNewswire/ -- Amorepacific Holdings announced that it signed a strategic investment agreement with HIGHER Corporation, a medical aesthetics company, to strengthen collaboration across beauty and medical aesthetics. Based on their respective...
Telix H1 2026 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026. An investor webcast and conference call will be held at 9:00 a.m....
Kuching to Host Asia’s Leading Diabetes Experts at “Diabetes Asia 2026” Conference (DAC 2026)
KUCHING, Malaysia, July 30, 2026 /PRNewswire/ -- As diabetes continues to place an increasing burden on Malaysia's healthcare system — affecting an estimated 4.75 million Malaysian adults - Kuching will become the regional meeting point for leading diabetes experts this October as it hosts the "Diabetes Asia 2026" Conference (DAC 2026). The conference will bring together internationally renowned...
AiRISTA Receives Frost & Sullivan’s 2026 North American Competitive Strategy Leadership Recognition for Healthcare Real-Time Location Solutions
The company's interoperable RTLS platform, customer-centric strategy, and continuous innovation are transforming healthcare asset management and operational efficiency. SAN ANTONIO, July 30, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that AiRISTA has received the 2026 North American Competitive Strategy Leadership Recognition in the healthcare asset management solutions industry for its outstanding achievements in competitive strategy, innovation, and...
HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates
HKEY-AI2Vivo™ 1.0 supports the move from computational hypotheses to in vivo translational evidence in autoimmune and allergy research BOSTON and SUZHOU, China, July 30, 2026 /PRNewswire/ -- HKeyBio has established HKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration Program. The program supports AI drug-discovery teams in translating AI-generated targets, molecules and mechanism hypotheses into in vivo pharmacology, mechanism,...
Insilico Medicine Launches the Industry’s First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a large-scale real-world "blind test" for frontier AI and foundation models, with a transparent public leaderboard. CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- As general-purpose and domain-specific AI models rapidly infiltrate drug discovery, one critical question looms over the pharmaceutical sector: Can these models...
NIPRO CORPORATION Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States
New medium-cutoff Dialyzer with a Super High-flux membrane brings NIPRO's approach to expanded hemodialysis to United States healthcare providers. OSAKA, Japan, July 30, 2026 /PRNewswire/ -- NIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food and Drug Administration (FDA), effective July 28, 2026. The clearance enables the introduction of HDs (Hemodialysis...
Continuity Biosciences Appoints Vicky Papoutsis to Board of Directors
Business development and corporate strategy executive joins Board as Company advances its clinical programs and partnering activity BRADENTON, Fla., July 30, 2026 /PRNewswire/ -- Continuity Biosciences today announced the appointment of Vicky Papoutsis to its Board of Directors. Vicky brings more than 25 years of biopharmaceutical business development and corporate strategy...
Ping An Group Upgrades Longevity Management Service System, Unveils 11 Health Longevity Centers Nationwide
SHANGHAI, July 30, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An Group") held a service upgrade press conference yesterday themed "Professionalism Safeguards a Century of Wellbeing", officially upgrading its "Ping An Health Longevity Management Service System". Relying on three core capabilities—medicine, AI, and cutting-edge technology—and through systematic risk prevention and proactive intervention, the system...
